| Curtis, Jeffrey |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
| Recruiting | 4 | 1000 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 02/24 | 09/24 | | |
| Active, not recruiting | 4 | 605 | US | Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland | Influenza | 12/24 | 05/25 | | |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
VERVE, NCT01967316: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users |
|
|
| Recruiting | 2 | 125 | US | Herpes Zoster Vaccine, Zostavax, Placebo, Normal Saline | University of Alabama at Birmingham, Oregon Health and Science University | Rheumatoid Arthritis | 06/16 | 06/16 | | |
VERVE, NCT02538757: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users |
|
|
| Active, not recruiting | 2 | 125 | US | Herpes Zoster Vaccine, Zostavax, Placebo, Normal Saline | University of Alabama at Birmingham, Oregon Health and Science University | Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease, Inflammatory Arthritis | 02/18 | 08/18 | | |
| Recruiting | N/A | 1000 | US | | Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, Columbia University, Johns Hopkins University, National Jewish Health, University of Alabama at Birmingham, University of California, Los Angeles, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University Health Sciences, Temple University, University of California, San Francisco, COPD Foundation, Mayo Clinic | COPD, Early-Onset | 01/25 | 04/25 | | |
NCT03631225: The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 1500 | US | Vectra | Sequenom, Inc., Laboratory Corporation of America | Rheumatoid Arthritis (RA) | 09/25 | 09/25 | | |
| Presti, Rachel |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 4 | 605 | US | Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland | Influenza | 12/24 | 05/25 | | |
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above |
|
|
| Active, not recruiting | 2 | 387 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA Investigational Vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 06/25 | | |
| Recruiting | 2 | 250 | US | Doxycycline, Placebo | Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan | Emphysema, HIV | 02/27 | 02/27 | | |
| Completed | N/A | 8 | US | Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content | Washington University School of Medicine, Janssen Scientific Affairs, LLC | HIV I Infection, Adiposity | 06/23 | 06/23 | | |
| Recruiting | N/A | 30 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection | 07/29 | 09/29 | | |
| Klebert, Michael K |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 4 | 605 | US | Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland | Influenza | 12/24 | 05/25 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) |
|
|
| Active, not recruiting | 2 | 90 | US | CMV-MVA Triplex, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Cytomegalovirus Infections, HIV Infections, Vaccine | 11/24 | 10/25 | | |
| Recruiting | 2 | 250 | US | Doxycycline, Placebo | Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan | Emphysema, HIV | 02/27 | 02/27 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, GS-2872, 10-1074-LS, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/26 | 04/26 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT05144386: Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART |
|
|
| Completed | 1 | 6 | US | EBT-101 | Excision BioTherapeutics | HIV-1-infection | 11/24 | 11/24 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Completed | N/A | 8 | US | Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content | Washington University School of Medicine, Janssen Scientific Affairs, LLC | HIV I Infection, Adiposity | 06/23 | 06/23 | | |
| Recruiting | N/A | 250 | US | Pathogen and Host Directed testing, Respiratory Pathogen ID/AMR Enrichment Panel (Illumina), Metagenomic Next Generation Sequencing (Illumina), T2 Bacteria Panel (T2 Biosystems), T2 Resistance Panel (T2 Biosystems), Procalcitonin (Abbott), TriVerity host (Inflammatix), Host gene expression, FilmArray Pneumonia Panel (BioFire) | Duke University, National Institute of Allergy and Infectious Diseases (NIAID) | Pneumonia, Bacterial, Ventilator Associated Pneumonia | 04/25 | 07/25 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| Recruiting | N/A | 30 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection | 07/29 | 09/29 | | |
| Parra-Rodriguez, Luis |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
| Rauseo, Adriana |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
| Active, not recruiting | 4 | 605 | US | Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland | Influenza | 12/24 | 05/25 | | |
| Bagchi, Shashwatee |
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations |
|
|
| Completed | 4 | 455 | US | Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics | Influenza, COVID-19 | 03/24 | 05/24 | | |
| Active, not recruiting | 4 | 605 | US | Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV) | Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland | Influenza | 12/24 | 05/25 | | |
